Alembic Ltd

NSE
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

Start SIP in Alembic Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
54.67% Gain from 52W Low
1.2
TTM PE Ratio
Below industry Median
9.9
Price to Book Ratio
Below industry Median
1.2
Dividend yield 1yr %
High in industry
2.3
TTM PEG Ratio
PEG TTM is less than 1
0.1
RSI
RSI is mid-range
53.9
MFI
MFI is mid-range
49.5

Alembic Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Alembic Ltd Result Highlights
  • Alembic Pharma reported 2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended December (Q3FY24). On a year-on-year (YoY) basis, it witnessed a growth of 8%.
  • Its expenses for the quarter were down by 1% QoQ and up 8% YoY.
  • The net profit grew 32% QoQ and 48% YoY.
  • The earnings per share (EPS) of Alembic Pharma stood at 9.2 during Q3FY24.

Read More

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Alembic Ltd shareholding Pattern

Promoter
70.9%
Foreign Institutions
1.1%
Public
28%
Promoter
70.9%
Foreign Institutions
0.9%
Public
28.2%
Promoter
70.9%
Foreign Institutions
0.8%
Mutual Funds
3.4%
Domestic Institutions
3.4%
Public
24.9%
Promoter
70.9%
Foreign Institutions
0.7%
Mutual Funds
3.9%
Domestic Institutions
3.9%
Public
24.4%
Promoter
70.9%
Foreign Institutions
0.7%
Mutual Funds
3.9%
Domestic Institutions
4%
Public
24.5%
Promoter
70.9%
Foreign Institutions
0.8%
Mutual Funds
3.9%
Domestic Institutions
4%
Public
24.3%
Mutual Funds
4.1%
Mutual Funds
4.2%

Alembic Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
94.20
10Day EMA
93.80
12Day EMA
93.60
20Day EMA
92.90
26Day EMA
92.60
50Day EMA
92.60
100Day EMA
91.20
200Day EMA
87.10
5Day SMA
94.10
10Day SMA
93.40
20Day SMA
92.90
30Day SMA
89.30
50Day SMA
93.40
100Day SMA
93.50
150Day SMA
89.10
200Day SMA
86.80
Delivery & Volume
Resistance & Support
95.12
Pivot
Resistance
First Resistance
96.23
Second Resistance
98.12
Third Resistance
99.23
Support
First Support
93.23
Second support
92.12
Third Support
90.23
Relative Strength Index
53.92
Money Flow Index
49.54
MACD
0.91
MACD Signal
0.64
Average True Range
3.49
Average Directional Index
16.85
Rate of Change (21)
14.29
Rate of Change (125)
20.42
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Ajmera Realty & Infra India Ltd.
2959.92
291.6
887.45
Unitech Ltd.
-
-
-
Arvind SmartSpaces Ltd.
3363.16
304.5
764
Marathon Nextgen Realty Ltd.
2261.77
273.1
533.7
EFC (I) Ltd.
-
-
-
Shriram Properties Ltd.
2077.13
62.4
140.9

Alembic Ltd Company background

Founded in: 1907
Managing director: Malika C Amin
Alembic Ltd is one of the Indias most experienced manufactures of bulk drugs and pharmaceuticals formulation in human and animal healthcare. The Company operates primarily in three lines of business, manufacture of Bulk Drugs, Real Estate and Power Generation through Windmills and Cogen Power Plant which is presently used for captive consumption for the operation of the Bulk Drugs Manufacturing plant at Vadodara. The Company has been dealing in Active Pharmaceutical Ingredient (API) Business and Real Estate Business.The company is a ISO9002 and ISO14001 certified company with manufacturing practices and facilities that conform to WHOGMP guidelines. They manufacture pharmaceuticals and chemicals, bulk drugs (penicillin and other antibiotics) and formulations. They are having their manufacturing facilities at Vadodara in Gujarat and Solan in Himachal Pradesh.Alembic Ltd was incorporated in the year 1907 with the name Alembic Chemical Works Co Ltd in Vadodara to manufacture tinctures and alcohol. They Started to manufacture cough syrup, vitamins, tonics and sulphur durgs in the year 1940. In the year 1961, they inaugrated the Pencillin Palnt. In the year 1968, they started to manufacture Streptomycin.In the 1971, they manufactured Erythromycin using expertise from Eli Lilly, USA and in the year 1972, they launched Althrocin, a brand of Erythromycin. In year 1997, Althrocin become top selling brand in India. In the year 2001, they started to manufacture Cephalosporin C. In June 2001, the company formed a wholly owned subsidiary company named Alembic Europe Pvt Ltd in UK.In the year 2005, the company has launched ZERO, a new generation, no calories, Sucralose Based Sugar Substitute which gave entry for the company into the highgrowth lifestyle OTC product segment. In May 2005, the generic alliances and API division were merged to form an independent SBU.The company has set up a formulation manufacturing facility at Baddi in Himachal Pradesh with a production capacity 900 million tablets and 600 million liquid oral bottles annually. During the year 200506, the company has increased the installed capacity of Tablets Capsules and Oral Preparation Ointments by 595 Million Nos and 720 MT respectively.During the year 200506, the company acquired API Plant at Karakhadi in Vadodara. In the year 2007, the company acquired the NonOncology Business of Dabur Pharma Ltd. Also in the same year, they entered into a licensing agreement for its Novel Drug Delivery Platform for Keppra XR with UCB Belgium. During the year 200708, the company acquired the API manufacturing facility of Nirayu Pvt Ltd at Panelav near Vododara.The Company formed a wholly owned subsidiary viz. Alembic Global Holding SA in Neuchatel, Switzerland in 2009. The Pharmaceutical Undertaking of the Company demerged and the same got transferred to Alembic Pharmaceuticals Limited with effect from Appointed date i.e. 1st April, 2010. The maiden real estate project Samsara was completed in 2014. The Company launched second real estate project, VEDA in 201516. It further launched two APIs in 2017. During year 201718, Alembic City Limited (formerly known as Alembic Exports Limited) became whollyowned subsidiary of the Company.During 201819, the Composite Scheme of Arrangement comprising of transfer and vesting of the Identified Real Estate Undertaking of Alembic Limited (the Company / the First Demerged Company) into Shreno Limited (the First Transferee Company/ the Second Demerged Company) and transfer and vesting of Engineering Division and Investment Division of Shreno Limited into Nirayu Private Limited (the Second Transferee Company) and their respective shareholders with effect from the Appointed Date i.e. 1st November, 2018 was sanctioned by the Honble National Company Law Tribunal, Ahmedabad Bench (NCLT) vide its order dated 26th July, 2019. Accordingly, Scheme was made effective from 26th July, 2019.The Company launched a residential project VEDA II during 2020.
Read More

Alembic Ltd FAQs

Alembic Ltd shares are currently priced at 94.35 on NSE and 94.2 on BSE as of 4/25/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Alembic Ltd [ALEMBICLTD] share was 52.91. The Alembic Ltd [ALEMBICLTD] share hit a 1-year low of Rs. 61 and a 1-year high of Rs. 107.65.

The market cap of Alembic Ltd is Rs. 2422.74 Cr. as of 4/25/2024 12:00:00 AM.

The PE ratios of Alembic Ltd is 27.79 as of 4/25/2024 12:00:00 AM.

The PB ratios of Alembic Ltd is 2.87 as of 4/25/2024 12:00:00 AM

You can easily buy Alembic Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage